# Krystal Biotech Q3 Estimates Point to 29.4% Revenue Growth

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/44962
Published: 2026-10-30T17:45:02.000Z
Updated: 2026-10-30T17:45:02.000Z
Section: Business

> Earnings per share are estimated at $1.92, down 27.8% year over year. Results are due before U.S. markets open Monday, Nov. 2.

Krystal Biotech (KRYS) has a third-quarter revenue estimate of $126.54 million, 29.4% above the year-earlier quarter. Earnings per share are estimated at $1.92, a 27.8% decline from a year earlier.

The company is scheduled to release results before U.S. markets open Monday, Nov. 2.